40
Participants
Start Date
September 30, 2005
Primary Completion Date
November 30, 2009
Study Completion Date
November 30, 2009
CNTO 328
Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.
Docetaxel
Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
Baltimore
New York
Chapel Hill
Philadelphia
Nashville
Lead Sponsor
Centocor, Inc.
INDUSTRY